Okyo Pharma Limited (OKYO)

Dec 12, 2024

OKYO Pharma : Results of AGM 2024 - Marketscreener.com

Dec 12, 2024

Dec 10, 2024

Contrasting Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO) - Defense World

Dec 10, 2024

Dec 03, 2024

Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN) - Defense World

Dec 03, 2024

Nov 28, 2024

OKYO Pharma (NASDAQ:OKYO) Trading Down 1% – What’s Next? - Defense World

Nov 28, 2024

Nov 26, 2024

OKYO Pharma to join BTIG Ophthalmology Day By Investing.com - Investing.com Canada

Nov 26, 2024

Nov 26, 2024

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference - GlobeNewswire

Nov 26, 2024

Nov 26, 2024

OKYO Pharma to join BTIG Ophthalmology Day - Investing.com

Nov 26, 2024

Nov 26, 2024

OKYO Pharma to Highlight Innovations at BTIG Conference - TipRanks

Nov 26, 2024

Nov 26, 2024

OKYO Pharma CEO to present at BTIG Ophthalmology Day - Proactive Investors USA

Nov 26, 2024

Nov 26, 2024

OKYO Pharma to Present at BTIG Ophthalmology Day, Showcases Neuropathic Pain Treatment | OKYO Stock News - StockTitan

Nov 26, 2024

Nov 25, 2024

Notice of AGM: December 2024 - Marketscreener.com

Nov 25, 2024

Nov 15, 2024

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire

Nov 15, 2024

Nov 07, 2024

OKYO Pharma (LON:OKYO) Trading Down 24.3% – Here’s What Happened - Defense World

Nov 07, 2024

Oct 30, 2024

OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference - Proactive Investors USA

Oct 30, 2024

Oct 30, 2024

OKYO Pharma Advances in Ocular Treatment Trials - TipRanks

Oct 30, 2024

Oct 30, 2024

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference - The Manila Times

Oct 30, 2024

Oct 30, 2024

OKYO Pharma Limited to Present at International Tear Film & Ocular Surface Society Conference - Marketscreener.com

Oct 30, 2024

Oct 26, 2024

OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialICYMI - Proactive Investors Australia

Oct 26, 2024

Oct 25, 2024

OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain - Proactive Investors Australia

Oct 25, 2024

Oct 25, 2024

H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares - Investing.com India

Oct 25, 2024

Oct 24, 2024

OKYO Pharma doses first subject in OK-101 Phase II trial for NCP - Clinical Trials Arena

Oct 24, 2024

Oct 24, 2024

H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares By Investing.com - Investing.com South Africa

Oct 24, 2024

Oct 24, 2024

Wainwright sustains Buy rating on OKYO Pharma shares on clinical trial progress - Investing.com

Oct 24, 2024

Oct 24, 2024

OKYO Pharma launches Phase 2 trial for NCP treatment - Investing.com India

Oct 24, 2024

Oct 23, 2024

OKYO Pharma commences Phase 2 trial for ocular pain treatment By Investing.com - Investing.com Australia

Oct 23, 2024

Oct 23, 2024

OKYO Pharma launches Phase 2 trial for NCP treatment By Investing.com - Investing.com Australia

Oct 23, 2024

Oct 23, 2024

OKYO Pharma shares surge on Phase 2 neuropathic corneal pain trial update - Proactive financial news

Oct 23, 2024

Oct 23, 2024

OKYO Pharma commences Phase 2 trial for ocular pain treatment - Investing.com India

Oct 23, 2024

Oct 23, 2024

OKYO Pharma Begins Key Trial for Eye Pain Therapy - TipRanks

Oct 23, 2024

Oct 23, 2024

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire

Oct 23, 2024

Oct 23, 2024

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire Inc.

Oct 23, 2024

Oct 21, 2024

Q2 Earnings Estimate for OKYO Pharma Issued By HC Wainwright - Defense World

Oct 21, 2024

Oct 17, 2024

H.C. Wainwright maintains Buy rating on OKYO Pharma shares By Investing.com - Investing.com UK

Oct 17, 2024

Oct 17, 2024

OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug - Yahoo Finance

Oct 17, 2024

Oct 16, 2024

OKYO Pharma begins phase 2 trial for NCP treatment - Investing.com

Oct 16, 2024

Oct 16, 2024

OKYO Pharma begins phase 2 trial for NCP treatment By Investing.com - Investing.com UK

Oct 16, 2024

Oct 16, 2024

OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment - Proactive Investors USA

Oct 16, 2024

Oct 16, 2024

OKYO begins patient enrollment for Phase 2 NCP trial By Investing.com - Investing.com Australia

Oct 16, 2024

Oct 16, 2024

OKYO begins patient enrollment for Phase 2 NCP trial - Investing.com

Oct 16, 2024

Oct 16, 2024

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - GlobeNewswire

Oct 16, 2024

Oct 04, 2024

OKYO Pharma (NASDAQ:OKYO) Shares Up 3% – What’s Next? - Defense World

Oct 04, 2024

Oct 01, 2024

Neuropathic Ocular Pain Market Overview: Size, Growth - openPR

Oct 01, 2024

Sep 24, 2024

Oklo Inc. (OKLO) is looking forward to a strong quarter - SETE News

Sep 24, 2024

Sep 23, 2024

Understanding OKLO’s book value per share for better investment insights - US Post News

Sep 23, 2024

Sep 23, 2024

XTX Topco Ltd Purchases 5,759 Shares of OneMain Holdings, Inc. (NYSE:OMF) - Defense World

Sep 23, 2024

Sep 23, 2024

Multibagger Stock under Rs 20: After stock split, Ok Play allots equities upon warrants conversion - ET Now

Sep 23, 2024